|Videos|January 18, 2023
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Topline results from the study are anticipated in the first half of 2027.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
2
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
3
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
4
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
5